Pacira BioSciences (PCRX) Total Debt (2010 - 2026)

Pacira BioSciences' Total Debt history runs 15 years deep, the most recent figure standing at $367.7 million for Q1 2026.

• On a quarterly basis, Total Debt rose 21.11% year-over-year to $367.7 million in Q1 2026; TTM through Mar 2026 was $367.7 million, a 21.11% increase from a year earlier, with the FY2025 full-year figure at $372.2 million, down 52.71% from the prior year.
• Total Debt slipped to $367.7 million in Q1 2026 per PCRX's latest filing, from $372.2 million in the prior quarter.
• Across five years, Total Debt topped out at $787.1 million in Q4 2024 and bottomed at $109.8 million in Q2 2024.
• The 5-year median for Total Debt is $309.8 million (2022), against an average of $337.3 million.
• Across the five-year window, Total Debt sank 61.93% in 2023 and jumped 173.55% in 2025, its largest moves.
• Year by year, Total Debt stood at $723.1 million in 2022, then fell by 26.56% to $531.1 million in 2023, then surged by 48.21% to $787.1 million in 2024, then slumped by 52.71% to $372.2 million in 2025, then declined by 1.22% to $367.7 million in 2026.
• Per Business Quant, the three latest PCRX Total Debt figures stand at $367.7 million (Q1 2026), $372.2 million (Q4 2025), and $376.7 million (Q3 2025).